semaglutide injection clinic slidell GLP-1 Weight Loss Program Semgo Semaglutide Injection | Cell

This led to the US FDA approval of Ozempic to reduce cardiovascular risk in this specific patient population in 2020 In the HARMONY Outcomes trial, patients with type 2 diabetes and cardiovascular disease who took the GLP-1 medication saw a 22% reduction in major adverse cardiovascular events compared to placebo

, , - ,

Particularly in patients who, due to mast cell activation syndrome (MCAS) or food intolerances, only eat limited amounts of food, it is crucial to ensure a sufficient intake of protein and, above all, essential amino acids

Greenfield and Gerald D

Importantly, GLP-1 receptor agonists also slow gastric emptyingthe rate at which food leaves the stomach and enters the small intestine